News
Globaldata's analysis focuses on three key indicators, which include HTA outcomes in the 5EU and the entry of newly priced ...
NewBiologix has given a non-exclusive technology licence to Recipharm Advanced Bio to provide pharma companies access to ...
HLS Therapeutics has signed an agreement with Esperion Therapeutics for commercialising Nexletol and Nexlizet in Canada.
The US Food and Drug Administration (FDA) has set an "aggressive" timeline to implement genAI across the agency by 30 June ...
Developing orphan drugs involves navigating intricate regulatory landscapes, financial risks, and limited clinical data. To ...
BioVaxys Technology and Sona Nanotech have signed an agreement to develop cancer therapeutics, utilising the DPX platform ...
The Vivo Opportunity Fund has already catalysed a plethora of medicine development via biotech investments in its first two ...
Apart from four billion-dollar deals valued at $1bn or more driven by large pharma, the industry remains cautious given the ...
Viralgen has partnered biotech company Trogenix, aiming to accelerate the development of gene therapy for glioblastoma.
ARS Pharmaceuticals has announced the availability of neffy (epinephrine nasal spray) 1mg in the United States.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results